Design of the EMPERIAL-preserved trial of empagliflozin in patients with chronic heart failure with preserved ejection fraction

被引：0

作者：

Ponikowski, P. ^{[1
]}

Abraham, W. T. ^{[2
]}

Lindenfeld, J. ^{[3
]}

Zeller, C. ^{[4
]}

Macesic, H. ^{[5
]}

Brueckmann, M. ^{[6
]}

Salsali, A. ^{[7
]}

Anker, S. D. ^{[8
]}

机构：

[1] Wroclaw Med Univ, Wroclaw, Poland

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[5] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada

[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany

[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[8] Charite, Berlin, Germany

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2018年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P269

引用

页码：48 / 49

页数：2

共 50 条

[21] A Dose Comparison Study of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
Macdonald, Blair J.
Turgeon, Ricky D.
CANADIAN JOURNAL OF CARDIOLOGY, 2024, 40 (03) : 388 - 388
[22] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
Yousef, Zaheer
HEART, 2022, 108 : A79 - A80
[23] Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial
Green, Jennifer
METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S25 - S25
[24] Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial
Anker, Stefan D.
CIRCULATION, 2021, 144 (25) : E571 - E572
[25] EFFECTS OF EMPAGLIFLOZIN IN FEMALE AND MALE PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS FROM THE EMPEROR-PRESERVED TRIAL
Butler, Javed
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 311 - 311
[26] Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
Butler, Javed
Siddiqi, Tariq Jamal
Filippatos, Gerasimos
Ferreira, Joao Pedro
Pocock, Stuart J.
Zannad, Faiez
Anker, Stefan D.
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) : 245 - 248
[27] Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
Boehm, Michael
Butler, Javed
Krawczyk, Marcin
Mahfoud, Felix
Haring, Bernhard
Filippatos, Gerasimos
Ferreira, Joao Pedro J.
Pocock, Stuart
Brueckmann, Martina
Ofstad, Anne Pernille
Schueler, Elke
Wanner, Christoph
Verma, Subodh
Packer, Milton D.
Anker, Stefan
EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1375 - 1383
[28] Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
Filippatos, Gerasimos
Farmakis, Dimitrios
Butler, Javed
Zannad, Faiez
Ferreira, Joao Pedro
Ofstad, Anne Pernille
Iwata, Tomoko
Brueckmann, Martina
Pocock, Stuart J.
Packer, Milton
Anker, Stefan D.
EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 970 - 977
[29] Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
Butler, Javed
Filippatos, Gerasimos
Siddiqi, Tariq Jamal
Ferreira, Joao Pedro
Brueckmann, Martina
Bocchi, Edimar
Bohm, Michael
Chopra, Vijay K.
Giannetti, Nadia
Iwata, Tomoko
Januzzi, James L.
Kaul, Sanjay
Pina, Ileana L.
Ponikowski, Piotr
Rauch-Krohnert, Ursula
Shah, Sanjiv J.
Senni, Michele
Sumin, Mikhail
Verma, Subodh
Zhang, Jian
Pocock, Stuart J.
Zannad, Faiez
Packer, Milton
Anker, Stefan D.
CIRCULATION, 2022, 146 (14) : 1046 - 1055
[30] Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Boehm, Michael
Anker, Stefan
Mahfoud, Felix
Lauder, Lucas
Filippatos, Gerasimos
Ferreira, Joao Pedro
Pocock, Stuart J.
Brueckmann, Martina
Saloustros, Ilias
Schueler, Elke
Wanner, Christoph
Zannad, Faiez
Packer, Milton
Butler, Javed
EUROPEAN HEART JOURNAL, 2023, 44 (05) : 396 - 407

← 1 2 3 4 5 →